Veracyte Announces Second Quarter 2024 Financial Results
Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors
Veracyte to Participate in Upcoming Investor Conferences
Veracyte Announces First Quarter 2024 Financial Results
Veracyte’s Prostate Test Receives Evidence-Level Rating Among Molecular Tests
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
Veracyte to Participate in the Raymond James 45th Annual Investors Conference
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results
Veracyte Completes Acquisition of C2i Genomics
In announcing plans on Monday to pay up to $95 million for C2i Genomics, Veracyte is betting that it will expand further along the cancer care continuum.